ArticleJournal of Cancer2017
Upregulation of Serum miR-10b Is Associated with Poor Prognosis in Patients with Melanoma.
Article in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Blood-based circulating microRNAs as diagnostic biomarkers in cutaneous melanoma: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Blood-based microRNAs as Potential Diagnostic Biomarkers for Melanoma: A Meta-Analysis.Current medicinal chemistry · 2024Pooled it
- Circulating miRNAs as biomarkers for the diagnosis in patients with melanoma: systematic review and meta-analysis.Frontiers in genetics · 2024Pooled it
- Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients.Molecular diagnosis & therapy · 2018Pooled it
- Targeting Spatiotemporal Heterogeneity of oncomiRNAs: A New Frontier in Cancer Therapy.Cancer reports (Hoboken, N.J.) · 2026Review
- Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Circulating non-coding RNAs as a tool for liquid biopsy in solid tumors.Epigenomics · 2025Review
- Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment.Molecular cancer · 2025Review
- Exosome-Derived microRNA: Implications in Melanoma Progression, Diagnosis and Treatment.Cancers · 2022Review
- Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma.Journal of translational medicine · 2022Review
- Promising Blood-Based Biomarkers for Melanoma: Recent Progress of Liquid Biopsy and Its Future Perspectives.Current treatment options in oncology · 2022Review
- Diagnostic, grading and prognostic role of a restricted miRNAs signature in primary and metastatic brain tumours. Discussion on their therapeutic perspectives.Molecular genetics and genomics : MGG · 2022Article
- MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.Frontiers in oncology · 2021Review
- Investigation of microRNA-10b values for the discrimination of metastasis due to melanoma.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Article
- miRNAs expression signature potentially associated with lymphatic dissemination in locally advanced prostate cancer.BMC medical genomics · 2020Article
- A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas.Cell communication and signaling : CCS · 2020Article
- High serum extracellular vesicle miR-10b expression predicts poor prognosis in patients with acute myeloid leukemia.Cancer biomarkers : section A of Disease markers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant expression of microRNAs (miRNAs) are believed to play a central role in the initiation and development of cancer. The aim of our study was to determine the clinical significance of serum miR-10b in melanoma. A total of 85 and 30 serum samples were obtained from patients with melanoma and healthy volunteers respectively. qRT-PCR was performed to evaluate the expression level of miR-10b in the melanoma cell lines and the serum samples from the participants. Then the clinical significance of serum miR-10b was further determined. Our results showed that the expression level of miR-10b was significantly increased in metastasis melanoma cells and melanoma patients compared to their respective controls. In addition, serum miR-10b expression level was able to discriminate melanoma patients from healthy volunteers as well differentiate melanoma patients at different clinical stage with high accuracy. Moreover, upregulation of serum miR-10b was positively associated with enhanced lymph node metastasis, advanced clinical stage and a shortened survival rate. Finally serum miR-10b was an independent prognostic factor for melanoma. Collectively, our study suggests that serum miR-10b level is upregulated in melanoma and associated with poor prognosis. It may be used as a potential prognostic biomarker for melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.